Paul Fineran

ORCID: 0000-0003-0051-3482
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Lysosomal Storage Disorders Research
  • Cytomegalovirus and herpesvirus research
  • Calcium signaling and nucleotide metabolism
  • Mycobacterium research and diagnosis
  • Tuberculosis Research and Epidemiology
  • Autoimmune and Inflammatory Disorders Research
  • Drug-Induced Hepatotoxicity and Protection
  • Drug Transport and Resistance Mechanisms
  • Liver Disease Diagnosis and Treatment
  • Pneumonia and Respiratory Infections
  • Diagnosis and treatment of tuberculosis
  • Autophagy in Disease and Therapy
  • Parkinson's Disease Mechanisms and Treatments
  • Respiratory viral infections research
  • COVID-19 Clinical Research Studies
  • Spectroscopy Techniques in Biomedical and Chemical Research
  • Complement system in diseases
  • Advancements in Transdermal Drug Delivery
  • Erythrocyte Function and Pathophysiology
  • Cellular transport and secretion
  • Phagocytosis and Immune Regulation
  • Glycogen Storage Diseases and Myoclonus

University of Edinburgh
2024-2025

Centre for Inflammation Research
2024

University of Oxford
2015-2020

Mansfield University
2020

University of Michigan
2016-2017

Acetyl-dl-leucine is a derivative of the branched chain amino acid leucine. In observational clinical studies, acetyl-dl-leucine improved symptoms ataxia, in particular patients with lysosomal storage disorder, Niemann-Pick disease type C1. Here, we investigated and its enantiomers acetyl-l-leucine acetyl-d-leucine symptomatic Npc1-/- mice observed improvement ataxia both individual acetyl-dl-leucine. When were administered pre-symptomatically to mice, treatments delayed progression extended...

10.1093/braincomms/fcaa148 article EN cc-by Brain Communications 2020-09-15

Niemann-Pick disease type C (NPC) is a lysosomal storage with heterogeneous neurodegenerative clinical course. Multiple therapies are in trials and inclusion criteria currently mainly based on age neurological signs, not taking into consideration differential individual rates of progression. In this study, we have evaluated simple metric, denoted annual severity increment score (ASIS), that measures rate progression could easily be used practice. We show ASIS stable over several years can to...

10.1186/s13023-018-0880-9 article EN cc-by Orphanet Journal of Rare Diseases 2018-08-16

<ns4:p><ns4:italic>Background. </ns4:italic>Tuberculosis remains a major global health concern. The ability to prevent phagosome-lysosome fusion is key mechanism by which intracellular mycobacteria, including<ns4:italic>Mycobacterium tuberculosis</ns4:italic>, achieve long-term persistence within host cells. mechanisms underpinning this pro-survival strategy remain incompletely understood. Host macrophages infected with persistent mycobacteria share phenotypic similarities cells taken from...

10.12688/wellcomeopenres.10036.1 preprint EN cc-by Wellcome Open Research 2016-11-18

<ns4:p><ns4:italic><ns4:bold>Background</ns4:bold>. </ns4:italic>Tuberculosis remains a major global health concern. The ability to prevent phagosome-lysosome fusion is key mechanism by which intracellular mycobacteria, including<ns4:italic>Mycobacterium tuberculosis</ns4:italic>, achieve long-term persistence within host cells. mechanisms underpinning this pro-survival strategy remain incompletely understood. Host macrophages infected with mycobacteria share phenotypic similarities cells...

10.12688/wellcomeopenres.10036.2 preprint EN cc-by Wellcome Open Research 2017-06-21

Drug-induced liver injury (DILI) is a challenge in clinical medicine and drug development. Highly sensitive novel biomarkers have been identified for detecting DILI following paracetamol overdose. The study objective was to evaluate biomarker performance 14-day trial of therapeutic dose paracetamol. PATH-BP double-blind, placebo-controlled, crossover study. Individuals (n = 110) were randomized receive 1 g 4× daily or matched placebo 2 weeks followed by 2-week washout before crossing over...

10.1093/toxsci/kfae031 article EN cc-by Toxicological Sciences 2024-03-21
Jannik Boos Caspar I. van der Made Gayatri Ramakrishnan Eamon Coughlan Rosanna Asselta and 95 more Britt-Sabina Löscher Luca Valenti Rafael de Cid Luis Bujanda Antonio Julià Erola Pairo-Castineira J. Kenneth Baillie Sandra May Berina Zametica Julia Heggemann Agustı́n Albillos Jesus M. Banales Jordi Barretina Natalia Blay Paolo Bonfanti Maria Buti Javier Fernandez Sara Marsal Daniele Prati Luisa Ronzoni Nicoletta Sacchi Valeria Rimoldi Elvezia Maria Paraboschi Alessandra Bandera Flora Peyvandi Giacomo Grasselli Francesco Blasi Francesco Malvestiti Serena Pelusi Cristiana Bianco Lorenzo Miano Angela Lombardi Pietro Invernizzi Alessio Gerussi Giuseppe Citerio Andrea Biondi Maria Grazia Valsecchi Marina Elena Cazzaniga Giuseppe Foti Ilaria Beretta Mariella D’Angiò Laura Rachele Bettini Xavier Farré Susana Iraola‐Guzmán Manolis Kogevinas Gemma Castaño‐Vinyals Koldo García‐Etxebarria Beatriz Nafría Jiménez Mauro D’Amato Adriana Palom Colin B. Begg Sara Clohisey Charles Hinds Peter Horby Julian C. Knight Lowell Ling David M. Maslove Daniel F. McAuley Johnny Millar Hugh Montgomery Alistair Nichol Peter Openshaw Alexandre C. Pereira Chris P. Ponting Kathy Rowan Malcolm G. Semple Manu Shankar‐Hari Charlotte Summers Timothy Walsh J. Kenneth Baillie Latha Aravindan Ruth Armstrong Heather Biggs Ceilia Boz Adam Brown Richard E. Clark Sara Clohisey Audrey Coutts J. Terrence Coyle Louise Cullum Sukamal Das Nicky Day Lorna Donnelly Esther Duncan Angie Fawkes Paul Fineran Max Head Fourman Anita Furlong James Furniss Bernadette Gallagher Tammy Gilchrist Ailsa Golightly Fiona Griffiths Katarzyna Hafezi Debbie Hamilton

Despite extensive global research into genetic predisposition for severe COVID-19, knowledge on the role of rare host variants and their relation to other risk factors remains limited. Here, 52 genes with prior etiological evidence were sequenced in 1,772 COVID-19 cases 5,347 population-based controls from Spain/Italy. Rare deleterious TLR7 present 2.4% young (<60 years) no reported clinical (n = 378), compared 0.24% (odds ratio [OR] 12.3, p 1.27 × 10

10.1016/j.xhgg.2024.100323 article EN cc-by-nc-nd Human Genetics and Genomics Advances 2024-06-28

<title>Abstract</title> Paracetamol overdose (POD) is common, with approximately 100,000 cases attending hospital emergency departments in the UK annually. Early treatment antidote <italic>N</italic>-acetylcysteine (NAC) crucial for patients who are at risk of developing life-threatening acute liver failure. A rapid point-of-care (POC) assay required to identify high-risk fit-for-purpose sensitivity and specificity facilitate early targeted NAC treatment. Here we demonstrate that measuring a...

10.21203/rs.3.rs-5565674/v1 preprint EN cc-by Research Square (Research Square) 2025-01-08

10.1016/bs.mcb.2014.10.025 article EN Methods in cell biology 2015-01-01

<ns4:p><ns4:italic><ns4:bold>Background</ns4:bold>. </ns4:italic>Tuberculosis remains a major global health concern. The ability to prevent phagosome-lysosome fusion is key mechanism by which intracellular mycobacteria, including<ns4:italic>Mycobacterium tuberculosis</ns4:italic>, achieve long-term persistence within host cells. mechanisms underpinning this pro-survival strategy remain incompletely understood. Host macrophages infected with mycobacteria share phenotypic similarities cells...

10.12688/wellcomeopenres.10036.2 article EN cc-by Wellcome Open Research 2017-06-21

Abstract Acetyl-DL-leucine (ADLL) is a derivative of the branched chain amino acid leucine. In observational clinical studies ADLL improved symptoms ataxia, in particular patients with lysosomal storage disorder (LSD), Niemann-Pick disease type C 1 (NPC1). Here, we investigated and its enantiomers acetyl-L-leucine (ALL) acetyl-D-leucine (ADL) symptomatic Npc1 -/- mice observed an improvement ataxia both ADLL. When ALL were administered pre-symptomatically to mice, treatments delayed...

10.1101/2020.05.20.105973 preprint EN bioRxiv (Cold Spring Harbor Laboratory) 2020-05-22
Coming Soon ...